Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.810
-0.040 (-2.16%)
Apr 29, 2026, 3:10 PM EDT - Market open
Milestone Pharmaceuticals Revenue
In the year 2025, Milestone Pharmaceuticals had annual revenue of $1.55M. Milestone Pharmaceuticals had revenue of $1.55M in the quarter ending December 31, 2025.
Revenue (ttm)
$1.55M
Revenue Growth
n/a
P/S Ratio
146.77
Revenue / Employee
$40,684
Employees
38
Market Cap
222.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Heron Therapeutics | 154.90M |
| Codexis | 70.39M |
| Fennec Pharmaceuticals | 44.64M |
| Voyager Therapeutics | 40.37M |
| Orchestra BioMed Holdings | 33.48M |
| Adagene | 7.67M |
| Camp4 Therapeutics | 3.50M |
MIST News
- 15 days ago - Milestone Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 19 days ago - Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT - GlobeNewsWire
- 22 days ago - Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 27 days ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - GlobeNewsWire
- 5 weeks ago - Why Milestone Pharma Stock Is Taking A Dive Today - Benzinga
- 5 weeks ago - Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - GlobeNewsWire